Friday, October 5, 2012
Theralase Commences Equity Financing
TORONTO, ONTARIO-- Oct. 4, 2011 - Theralase Technologies Inc. (TSX-V:TLT) announced today that it has commenced raising funds from accredited investors in a non-brokered private placement (the "Private Placement") of up to 2,000,000 units (the "Units") at a price of CND $0.25 per Unit for gross proceeds of up to CDN $500,000.00. Each Unit consists of one common share in the capital of the Company and one-half of one non- transferable common share purchase warrant (a "Warrant"). Each whole Warrant entitles the holder to purchase one additional common share (a "Warrant Share") in the capital of the Company for 1 year after closing at a price of CDN $0.38 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a four month holding period, commencing upon closing.
The company intends to utilize the proceeds of the Private Placement to provide additional working capital to further develop the Company's prospects in a number of areas, specifically:
· Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network
· Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of cancers, bacteria and viruses
· TLC-1000 therapeutic medical laser USA sales and marketing expansion
· TLC-2000 therapeutic medical biofeedback laser commercialization
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing in both humans and animals. Theralase complies with all FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and high quality products. Theralase also develops patented Photo Dynamic Compound (PDC) technology focused at targeting and destroying cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.
For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information, please contact:
President and CEO
416-447-8455 ext. 225
Chief Financial Officer
416-447-8455 ext. 224
Director of Investor Relations
416-447-8455 ext. 262